Tocagen's brain cancer gene therapy trial continues. Investors worry

Tocagen's brain cancer gene therapy trial continues. Investors worry

STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

By ADAM FEUERSTEIN

MICHELLE MONJE/STANFORD UNIVERSITY/NIH

Tocagen's Phase 3 clinical trial of a gene therapy for aggressive brain tumors will continue to a final analysis, a decision that will be debated.

READ MORE